167 related articles for article (PubMed ID: 22830443)
1. Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer.
Freeman DJ; McDorman K; Ogbagabriel S; Kozlosky C; Yang BB; Doshi S; Perez-Ruxio JJ; Fanslow W; Starnes C; Radinsky R
Mol Cancer; 2012 Jul; 11():47. PubMed ID: 22830443
[TBL] [Abstract][Full Text] [Related]
2. Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor.
Freeman DJ; Bush T; Ogbagabriel S; Belmontes B; Juan T; Plewa C; Van G; Johnson C; Radinsky R
Mol Cancer Ther; 2009 Jun; 8(6):1536-46. PubMed ID: 19509246
[TBL] [Abstract][Full Text] [Related]
3. A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.
Emanuel SL; Engle LJ; Chao G; Zhu RR; Cao C; Lin Z; Yamniuk AP; Hosbach J; Brown J; Fitzpatrick E; Gokemeijer J; Morin P; Morse BA; Carvajal IM; Fabrizio D; Wright MC; Das Gupta R; Gosselin M; Cataldo D; Ryseck RP; Doyle ML; Wong TW; Camphausen RT; Cload ST; Marsh HN; Gottardis MM; Furfine ES
MAbs; 2011; 3(1):38-48. PubMed ID: 21099371
[TBL] [Abstract][Full Text] [Related]
4. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
Niu G; Li Z; Xie J; Le QT; Chen X
J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473
[TBL] [Abstract][Full Text] [Related]
5. Correlation of pharmacokinetics with the antitumor activity of Cetuximab in nude mice bearing the GEO human colon carcinoma xenograft.
Luo FR; Yang Z; Dong H; Camuso A; McGlinchey K; Fager K; Flefleh C; Kan D; Inigo I; Castaneda S; Rose WC; Kramer RA; Wild R; Lee FY
Cancer Chemother Pharmacol; 2005 Nov; 56(5):455-64. PubMed ID: 15947929
[TBL] [Abstract][Full Text] [Related]
6. Augmentation of radiation response by panitumumab in models of upper aerodigestive tract cancer.
Kruser TJ; Armstrong EA; Ghia AJ; Huang S; Wheeler DL; Radinsky R; Freeman DJ; Harari PM
Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):534-42. PubMed ID: 18793955
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy of Sym004, novel anti-EGFR antibody mixture, in esophageal squamous cell carcinoma cell lines.
Fukuoka S; Kojima T; Koga Y; Yamauchi M; Komatsu M; Komatsuzaki R; Sasaki H; Yasunaga M; Matsumura Y; Doi T; Ohtsu A
Oncotarget; 2017 Feb; 8(7):11020-11029. PubMed ID: 28038457
[TBL] [Abstract][Full Text] [Related]
8. Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.
Leeman-Neill RJ; Cai Q; Joyce SC; Thomas SM; Bhola NE; Neill DB; Arbiser JL; Grandis JR
Clin Cancer Res; 2010 May; 16(9):2571-9. PubMed ID: 20388852
[TBL] [Abstract][Full Text] [Related]
9. Preclinical modeling of EGFR inhibitor resistance in head and neck cancer.
Quesnelle KM; Wheeler SE; Ratay MK; Grandis JR
Cancer Biol Ther; 2012 Aug; 13(10):935-45. PubMed ID: 22785204
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of triple-negative breast cancer models by combinations of antibodies to EGFR.
Ferraro DA; Gaborit N; Maron R; Cohen-Dvashi H; Porat Z; Pareja F; Lavi S; Lindzen M; Ben-Chetrit N; Sela M; Yarden Y
Proc Natl Acad Sci U S A; 2013 Jan; 110(5):1815-20. PubMed ID: 23319610
[TBL] [Abstract][Full Text] [Related]
11. STAT1 Activation Is Enhanced by Cisplatin and Variably Affected by EGFR Inhibition in HNSCC Cells.
Schmitt NC; Trivedi S; Ferris RL
Mol Cancer Ther; 2015 Sep; 14(9):2103-11. PubMed ID: 26141950
[TBL] [Abstract][Full Text] [Related]
12. Novel EGFR-specific immunotoxins based on panitumumab and cetuximab show in vitro and ex vivo activity against different tumor entities.
Niesen J; Stein C; Brehm H; Hehmann-Titt G; Fendel R; Melmer G; Fischer R; Barth S
J Cancer Res Clin Oncol; 2015 Dec; 141(12):2079-95. PubMed ID: 25899161
[TBL] [Abstract][Full Text] [Related]
13. Elevated RET expression enhances EGFR activation and mediates EGFR inhibitor resistance in head and neck squamous cell carcinoma.
Lin C; Lu W; Ren Z; Tang Y; Zhang C; Yang R; Chen Y; Cao W; Wang L; Wang X; Ji T
Cancer Lett; 2016 Jul; 377(1):1-10. PubMed ID: 27090738
[TBL] [Abstract][Full Text] [Related]
14. Preclinical evaluation of a monoclonal antibody targeting the epidermal growth factor receptor as a radioimmunodiagnostic and radioimmunotherapeutic agent.
Ray GL; Baidoo KE; Wong KJ; Williams M; Garmestani K; Brechbiel MW; Milenic DE
Br J Pharmacol; 2009 Aug; 157(8):1541-8. PubMed ID: 19681874
[TBL] [Abstract][Full Text] [Related]
15. Erlotinib is a viable treatment for tumors with acquired resistance to cetuximab.
Brand TM; Dunn EF; Iida M; Myers RA; Kostopoulos KT; Li C; Peet CR; Wheeler DL
Cancer Biol Ther; 2011 Sep; 12(5):436-46. PubMed ID: 21725209
[TBL] [Abstract][Full Text] [Related]
16. Preclinical activity of EGFR and MEK1/2 inhibitors in the treatment of biliary tract carcinoma.
Cavalloni G; Peraldo-Neia C; Varamo C; Chiorino G; Sassi F; Aglietta M; Leone F
Oncotarget; 2016 Aug; 7(32):52354-52363. PubMed ID: 27429047
[TBL] [Abstract][Full Text] [Related]
17. Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expression.
Zhao S; Kuge Y; Zhao Y; Takeuchi S; Hirata K; Takei T; Shiga T; Dosaka-Akita H; Tamaki N
BMC Cancer; 2013 Nov; 13():525. PubMed ID: 24191959
[TBL] [Abstract][Full Text] [Related]
18. Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma.
Hosono H; Takei J; Ohishi T; Sano M; Asano T; Sayama Y; Nakamura T; Yanaka M; Kawada M; Harada H; Kaneko MK; Kato Y
Int J Mol Med; 2020 Oct; 46(4):1443-1452. PubMed ID: 32945346
[TBL] [Abstract][Full Text] [Related]
19. Safety and pharmacokinetics of panitumumab in Japanese patients with advanced solid tumors.
Doi T; Ohtsu A; Tahara M; Tamura T; Shirao K; Yamada Y; Otani S; Yang BB; Ohkura M; Ohtsu T
Int J Clin Oncol; 2009 Aug; 14(4):307-14. PubMed ID: 19705240
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiles can predict panitumumab monotherapy responsiveness in human tumor xenograft models.
Boedigheimer MJ; Freeman DJ; Kiaei P; Damore MA; Radinsky R
Neoplasia; 2013 Feb; 15(2):125-32. PubMed ID: 23441127
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
